Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1949 Target Snapshot

Peptidyl-prolyl cis-trans isomerase A · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
521Compounds
135Assays
3Approved Drugs
623.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

Peptidyl-prolyl cis-trans isomerase A shows approved-linked disease relevance led by conjunctivitis. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt P62937. Start with conjunctivitis, then reuse UniProt P62937 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with conjunctivitis, then reuse UniProt P62937 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
conjunctivitis

Peptidyl-prolyl cis-trans isomerase A shows approved-linked disease relevance led by conjunctivitis. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with conjunctivitis because it currently carries approved-linked support. Linked drugs include CYCLOSPORINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Peptidyl-prolyl cis-trans isomerase A as ChEMBL target CHEMBL1949, mapped to UniProt P62937. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Peptidyl-prolyl cis-trans isomerase A
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1949
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
P62937
Peptidyl-prolyl cis-trans isomerase A
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Peptidyl-prolyl cis-trans isomerase A is the right protein anchor across sources, using UniProt P62937 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why conjunctivitis is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NamePeptidyl-prolyl cis-trans isomerase A
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP62937
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelPeptidyl-prolyl cis-trans isomerase A
UniProt AccessionP62937
Component TypeProtein
Sequence Length165 aa

Peptidyl-prolyl cis-trans isomerase A

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Peptidyl-prolyl cis-trans isomerase A, mapped to UniProt P62937. Sequence length is 165 aa.

Mapped IDP62937
Review namePeptidyl-prolyl cis-trans isomerase A
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Peptidyl-prolyl cis-trans isomerase A shows approved-linked disease relevance led by conjunctivitis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
conjunctivitis
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Approved-linked Approved
corneal disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Approved-linked Approved
eye disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Approved-linked Approved
immune system disease
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Approved-linked Approved
inflammation
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Approved-linked Approved
keratitis
1 linked drug · 1 direct · 1 efficacy
Linked drugCYCLOSPORINE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with conjunctivitis because it currently carries approved-linked support. Linked drugs include CYCLOSPORINE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseconjunctivitis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

3
Approved
2
Phase III
6
Phase II
Assay Mix

Activity Type Distribution

IC50290.0
KI80.0
KD253.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL3704747 9.51 IC50 0.31 Preclinical
CHEMBL1651956 9.47 Ki 0.34 Clinical
CHEMBL5759368 9.3 Kd 0.5 Preclinical
CHEMBL5792144 9.3 Kd 0.5 Preclinical
CHEMBL5812164 9.3 Kd 0.5 Preclinical
CHEMBL6051666 9.3 Kd 0.5 Preclinical
CHEMBL3344501 9.22 Kd 0.6 Preclinical
CHEMBL5791301 9.22 Kd 0.6 Preclinical
CHEMBL5810211 9.22 Kd 0.6 Preclinical
CHEMBL5856868 9.22 Kd 0.6 Preclinical
Distribution

pChEMBL Value Distribution

21
5.0
16
5.5
68
6.0
36
6.5
32
7.0
57
7.5
81
8.0
87
8.5
39
9.0
1
9.5
pChEMBL
Approved Drugs

Approved Drugs

CYCLOSPORINE
CHEMBL160
Approved 1983
Properties Compare Identifier
Assay Landscape

Assay Landscape

135
Total Assays
426
Tested Compounds
2
Assay Types
Binding — 134 assays, 426 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 88 273 7.0
assay format 34 152 8.1
cell-based format 10 1 8.0
tissue-based format 2 0 —
Functional — 1 assays, 19 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 19 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine